Hormone receptor mRNA and protein levels as predictors of premenopausal tamoxifen benefit.

Terese EngströmMaria EkholmMårten FernöChristine LundgrenBo NordenskjöldOlle StålPär-Ola BendahlJulia TutzauerLisa Rydén

Published in: Acta oncologica (Stockholm, Sweden) (2024)

These methods can all identify patients that benefit from 2 years of tamoxifen with equal performance, indicating that GEX data might be used to guide adjuvant tamoxifen therapy.

Keyphrases

breast cancer cells
estrogen receptor
positive breast cancer
ejection fraction
newly diagnosed
early stage
postmenopausal women
binding protein
stem cells
electronic health record
big data
chronic kidney disease
patient reported outcomes
cell therapy
artificial intelligence
patient reported
data analysis